Central retinal vein occlusion (CRVO) is typically a disease of older patients, rarely occurring before the third decade' and is associated with either an underlying vascular disease or a procoagulant state. Hypertension, diabetes, vasculitides, and hyperlipidaemia are the most commonly associated vascular disorders while the recognised procoagulant states include thrombocytosis, polycythaemia, macroglobulinaemia, the oral contraceptive pill, or systemic lupus erythematosus (SLE). The latter, however, has only been associated with CRVO in the presence of the lupus anticoagulant (LAC) and/or antiphospholipid antibodies (APLA).' LAC/APLA are associated with the increased thrombogenic potential of SLE but other fac during dose reduction but was eventually controlled on 5 mg of prednisolone daily.
One month later, the patient re-presented with symptoms of "shadows" in the right visual field of her right eye and ophthalmological and fluoroscein angiographic findings confirmed non-ischaemic CRVO. The full blood count was normal and procoagulant investigations were undertaken. The LAC was excluded with a normal APTT, Russell Viper Venom time, thromboplastin inhibition time, and platelet neutralisation procedure. Furthermore, when dilutional assays of factors VIII, IX and X were plotted and compared with pooled normal plasma, these lines were parallel excluding the presence of an inhibitor to these factors. Enzyme linked immunosorbent assays (ELISA) for IgG, IgM and IgA APLA were negative. Antigenic (laurell rocket immunoelectrophoresis) and functional protein C assays (chromogenic and clot methods) were normal, as were the antigenic and functional antithrombin III levels, heparin cofactor II, euglobulin clot lysis time, tissue plasminogen activator, and plasminogen activator inhibitor. Antigenic assay (laurell rocket immunoelectrophoresis) for total protein S was normal at 97% (normal 50-150%) but free protein S assay, performed by polyethylene glycol precipitation ofbound protein S followed by laurell immunoelectrophoresis, displayed a marked initial reduction at 24% (normal 50-130%). A second sample drawn three days later confirmed these assay results. There was a progressive increase in the free protein S concentration over the next eight months, eventually reaching the low normal range (52%) (figure). Functional protein S studies were also performed (clot and chromogenic assays) with similar results observed. Total and free protein S concentrations of the patient's parents and only sibling were normal on two separate occasions as were the assays for activated protein C resistance. At the time of thrombosis, the C4BP assay (The Binding Site) showed a significant elevation at 410 mg/l (normal 280-340 mg/l) and this was also followed over the ensuing eight months (figure).
To investigate for the presence of a protein S inhibitor, serial dilutions ofthe patient's plasma were added to pooled normal plasma and free and total protein S concentrations determined as described above. No accelerated reduction in normal plasma protein S concentrations was evident. Similarly, to investigate for the presence of an abnormal or reduced third component (C-3) (see discussion), serial dilutions of pooled normal plasma were added to the patient's plasma and also to a control sample from a patient with congenital protein S deficiency (25%). As normal pooled plasma was added with increasing concentration, the protein S concentrations progressively increased in both patient and control samples but with no significant differences between the two. At the time of thrombosis, the ANA titre was 1 in 2560 and anti-DNA antibodies 80 IU/l. Complement levels remained normal throughout the patient's illness. Prednisolone therapy was increased to 15 mg daily and later reduced to 5 mg and aspirin 150 mg daily was added. There was progressive resolution of the CRVO over the next month and the patient remains clinically stable some eight months after presentation.
Discussion
Congenital protein S deficiency, low concentrations of protein S in association with LAC/APLA or autoimmune protein S antibodies increase thrombotic risk.478 Furthermore, congenital protein S deficiency is a major predisposing factor for retinal vascular and cerebral sinus thrombosis including CRVO, central retinal artery occlusion and dural sinus thrombosis.9 However, low protein S concentrations are also detected in association with pregnancy, the oral contraceptive pill, nephrotic syndrome, disseminated intravascular coagulation, vitamin K deficiency, liver disease, and HIV infection but an increased prothrombotic tendency does not clearly exist in these settings.'0 In the absence of the above factors we investigated the role played by active SLE, low free protein S and elevated C4BP concentrations in predisposing our patient to the development of a CRVO at such an unusually young age.
Protein S exists in two forms, free (38-40%) and bound (60-62%). In the bound form it is non-functional and binds reversibly to C4BP. The free form functions as a protein C cofactor and plays an important antithrombotic role. C4BP not only binds protein S via its single v chain, but also independently regulates complement activation via its seven a chains by accelerating the decay of the classical pathway enzyme C-3 convertase.346 As there is a 1 to 1 stoichiometric relation between protein S and P chain C4BP, when the latter rises there should also be a subsequent increase in protein S binding with a resultant reduction in free protein S concentrations.3 C4BP concentrations increase with acute inflammation such as SLE46 but this concentration can vary depending on the coexistence of a LAC.5" It has been suggested that a reduction in free protein S concentrations through this mechanism could result in an increased risk of thrombosis.6 Although this postulate has been supported by in o -LIv vivo primate models,10 not all studies support it and some have found contradictory evidence.71' Similarly, our initial results would concur with the scenario of C4BP elevation being the primary initiating event followed by binding of protein S resulting in a reduction in free protein S, however, the progressive increase in C4BP in conjunction with the normalisation of free protein S concentrations cannot be explained by this postulate alone. It appears that, with time, a proportion of the patient's C4BP was incapable of binding protein S. A possible explanation is that there was an initial increase predominantly in C4BP 3 chain concentrations followed by a relative increase in C4BP ot chain concentrations, which would be incapable of binding protein s. 346 An autoimmune anti-protein S antibody has been recongised and is associated with a prothrombotic state8 but this antibody was directed against both free and bound protein S resulting in noticeably reduced concentrations of both forms of circulating protein S. In our patient there was a reduction in free protein S concentrations only, thus if an antibody was involved it would have to be directed against an epitope that was exposed only when protein S was not bound to C4BP. Furthermore, in the mixing studies, the addition of an antibody in the patient's plasma to the pooled normal plasma should have resulted in a reduction in free protein S concentrations, which did not occur. Similarly, if C-3, which normally assists protein S/C4BP binding,3 was deficient or abnormal, normalisation of the free protein S concentrations should have occurred rapidly in the mixing studies as C-3 was provided by the pooled normal plasma. An association between thromboembolism and corticosteroid therapy has been suggested'2 but the correlation may be more closely related to the disorder for which the treatment is required and therefore the contribution of steroid therapy to the development ofthrombosis is difficult to delineate precisely. Although hormonal effects as well as danazol can influence protein S and C4BP concentrations'01' this has not previously been the case with prednisolone. 7 The treatment of our patient was effective in controlling symptoms and preserving central retinal vein patency. Immunosuppressive and danazol therapy have been attempted with somewhat paradoxical changes in protein S and C4BP concentrations. " Given the young age of our patient for developing a CRVO, the absence of a LAC, APLA (although occasionally thromboses may precede the appearance of APLA), anti-protein S antibody and abnormal C3, the high C4BP concentrations at diagnosis was probably the initiating event followed by the reduction in free protein S concentrations leading to thrombus formation. The failure of C4BP to normalise in tandem with the free protein S concentrations was atypical of the previous in vitro findings of other investigators' " but this lack of clinical correlation with the in vitro data dealing with protein S and C4BP concentrations in SLE has been recognised elsewhere.71' Further recognition of the interrelation between SLE, C4BP, protein S, and thrombosis should lead to a better understanding of the clinical relation between SLE and thrombotic events.
